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Reply 
Our study (I) concerned a satellite protocol of the large scale 
placebo-controlled Anglo-Scandinavian Study of Early Thromboly-
sis (ASSET) study, which was started in November 1986 (2). Until 
its termination on February 29, 1988, >S,OOO patients with acute 
ischemic heart disease were allocated to therapy with placebo or 
recombinant tissue-type plasminogen activator (rt-PA). Neither we 
nor the scientific ethical committee of Denmark considered it 
unethical to conduct a small placebo-controlled satellite study 
starting on October I, 1987. In evaluating the ethical considerations 
at that time we assessed all available data including, as mentioned 
by Geraci, the documentation that thrombolytic therapy with strep-
tokinase or anisoylated plasminogen streptokinase activator com-
plex (APSAC) reduces the mortality rate in patients with acute 
myocardial infarction (3,4), the risk of serious bleeding complica-
tions and, in particular, the absence of knowledge about the clinical 
efficacy of rt-PA therapy. The results of the ASSET study were 
published on September 3, 1988 (2) >3 months after we had stopped 
including patients in our investigation (I,S). The ASSET study was 
prematurely terminated on February 29, 1988 because the ethical 
committee of that study considered it unethical to allocate patients 
with acute myocardial infarction to placebo treatment (2). Having 
learned of their decision, we stopped allocating patients to placebo 
treatment on the next day. These ethical aspects of our study are 
described in detail in a separate investigation (S). 
We consider the arguments forwarded by Geraci to be somewhat 
simplistic. His ethical judgments of scientific investigators are based 
on retrospective considerations and focus only on the dates in the 
total process of conducting placebo-controlled studies. These dates, 
and particularly the dates of termination of such studies, are an 
essential part of the information and should be correct. We suggest 
that Geraci improve his figure by indicating the premature termina-
tion of the ASSET study and our investigation. 
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LETTERS TO THE EDITOR 
Diastolic Function in 
Hypertrophic Cardiomyopathy 
1303 
Nihoyannopoulos et al. (I) are to be congratulated on their study 
correlating Doppler indexes of diastolic filling at rest with exercise 
capacity in patients with hypertrophic cardiomyopathy. The large 
number of patients involved make this an important contribution. 
However, several important methodologic considerations limit the 
ability to draw conclusions regarding the mechanism of exercise 
intolerance in the study patients. 
\. Fifty percent of the patients had at least mild mitral regurgi-
tation. With the exercise-induced increase in systolic blood pres-
sure, the degree of mitral regurgitation would be expected to 
increase. In addition to potentially altering results of Doppler 
indexes of diastolic left ventricular filling, significant mitral regurgi-
tation would also be expected to limit exercise capacity. 
2. It is not stated whether an attempt was made to detect 
concomitant ischemic heart disease, another possible source of 
exercise limitation. Up to 20% of patients in another study of 
hypertrophic cardiomyopathy (2) had associated significant coro-
nary artery disease and the prevalence was greater in older patients. 
The patients studied by Nihoyannopoulos et al. ranged in age up to 
74 years and nearly SO% had exertional chest pain. 
3. During data collection, nearly SO% of the patients were taking 
negative inotropic and chronotropic medications such as verapamil 
and beta-adrenergic blocking agents, and nearly all were taking 
amiodarone. Although the effect of amiodarone is less well docu-
mented, in normal subjects, beta-blockers significantly limit exer-
cise capacity (3) and calcium channel blockers may significantly 
alter Doppler filling indexes (4). Because presumably none of the 
normal subjects had mitral regurgitation, possible concomitant 
ischemic heart disease or concurrent cardioactive medication use, 
these factors may have confounded the interpretation of the data. 
4. The patient group was quite heterogeneous with respect to 
age, distribution of hypertrophy and presence of mitral regurgitation 
and left ventricular outflow tract obstruction; these factors could 
independently alter Doppler filling indexes, and this heterogeneity 
could have limited the ability to correlate these indexes with 
maximal oxygen consumption. 
S. Because age substantially affects maximal oxygen consump-
tion (S), did the subset of normal subjects who underwent exercise 
testing represent a close age match for the patient group? Finally, 
the maximal oxygen consumption levels shown for the normal 
subjects are those one would expect from well conditioned subjects, 
particularly if they were age matched to the patients. Unfortunately, 
the previous study from their laboratory referenced in the Methods 
section (6) does not describe the physical activity status of the 
normal subjects. Because degree of physical conditioning is another 
important independent determinant of maximal oxygen consump-
tion (S), and because it is doubtful that patients who had the 
symptoms noted in the Methods section were very active, a group of 
sedentary subjects may have been a more appropriate control group. 
An additional concern is that of potential overlap of patient data 
sets. Were any of the patients in their previous study (6) included in 
the present one? If so, did they undergo separate exercise testing for 
this present study? If not, because the exercise testing methodology 
in the previous study included invasive hemodynamic monitoring 
for the patients, this represents another potential difference from the 
